Single Domain Antibodies: From Conformational Sensors to Bispecific Antibodies for Immunotherapy

Video   Dec 23, 2016

 

Single domain antibodies (AKA nanobodies), the variable domains of some camelid antibodies, have interesting properties, including high production yields and stability but also the ability to bind unusual epitopes such as cleft and cavities. We are using them as innovative tools such as biosensors able to capture the conformation states of some membrane receptors such as EGFR or metabotropic glutamate receptors (mGluRs) on living cells. Combined with time-resolved FRET assays, they can reveal the fine mechanisms of receptor activation at the cell surface.Single domain antibodies also represent efficient building blocks to create bispecific molecules that we are using to immunomolulate effectors cells in the tumor microenvironment. An example will be given with the activation of effector cells such as NK cells in the context of tumor cells expressing low amount of tumor antigens, outperforming the classical ADCC mechanisms.

 
 
 
 

Recommended Videos

Study Shows HPV-vaccine Against Cervical Cancer is Working

Video

Girls in the first birth cohort to be offered and receive the HPV vaccine showed a lower degree of dysplasia which may eventually lead to cervical cancer than a birth cohort from 1983. This is the conclusion of a new study conducted by researchers at the University of Copenhagen, who have been the first to study the vaccine’s effect on the general population.

WATCH NOW

LC-MS/MS for Bioanalytical Peptide and Protein Quantification: MS Considerations

Video

Caitlin Dunning, Associate Scientist, discusses how to use mass spectrometry to develop sensitive, selective, and robust quantification methods for peptide and protein quantification, including: basic mass spectrometry considerations, MS tuning, and best practices for success.

WATCH NOW

Targeting Tumors: Challenges of Antibody-Drug Conjugates

Video

More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Biopharma Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy